Faes Farma


Q1 21 – a mixed bag

04/05/21 -"In Q1 21, Faes witnessed a material sales decline in its Bilastine franchise – impacted by Q1 20 ‘forward stocking’ and decline in the anti-histamine market – which overshadowed the decent showing in ..."

Pages
52
Language
English
Published on
04/05/21
You may also be interested by these reports :
07/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...

06/05/21
Benefiting from the strong uptake of the subcutaneous formulation and continued market share gain across lines, Darzalex reported ...

05/05/21
2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this ...

05/05/21
Merck’s preliminary figures came in a bit out of the blue, but street expectations were too moderate (adjusted EBITDA: -15%). We were more positive, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO